If you're looking for qedtx.com.com's Adword's Competitors iSpionage Competitor Research is the right product for you
Top Competitors for qedtx.com
| PPC Budget | # Keywords | # Overlap kw | ||
|---|---|---|---|---|
| prescriptiontreatmentwebsite | $784,154 | 110,530 | 7 | Learn More |
| umiamihealth.org | $26 | 55 | 4 | Learn More |
| mskcc.org | $14,321 | 7,309 | 4 | Learn More |
| cancercenter.com | $59,344 | 16,970 | 3 | Learn More |
| cholangiocarcinoma.org | $17 | 11 | 2 | Learn More |
Competitor offers & landing pages
Sample SEO Keywords for: qedtx.com
Organic Listings | 1st Page Keywords | Avg Pos | Pos Trend | Est.Traffic | Traffic Value | |
|---|---|---|---|---|---|---|
QED Therapeutics Infigratinib (BGJ398) is an or | 3 | 4 ( 6 ) | 230 | $2 | ||
| Keyword | Position | Trend | Search Vol | CPC | ||
| qed financial | 4 | 20 | $5.33 | |||
| bgj398 | 10 | 210 | $3.48 | |||
| q.e.d. | 20 | 0 | N /A | |||
A phase II study of infigratinib (BGJ398), an FGFR ... - QED Therapeutics https://qedtx.com/wp-content/uA phase II study of infigratin | 1 | 4 | 210 | $2 | ||
| Keyword | Position | Trend | Search Vol | CPC | ||
| bgj398 | 4 | 210 | $3.48 | |||
Top Ads
QED is studying options for - bile duct cancer treatment Discover more about research from QED. Learn more about QED's clinical trials, which are currently enrolling. Therapeutics Pipeline. Learn more about QED. www.qedtx.com/discover/infigratinib FGFR pathways may contribute | to many cancers and diagnoses, FGFR aberrations drive disease in more than 100,000 new diagnoses each year in the US. 1 in 5 cases of cholangiocarcinoma (bile duct cancer) may harbor FGFR aberrations. Learn more about QED. Therapeu www.qedtx.com/discover/infigratinib QED is studying options for - bile duct cancer treatment Discover more about research from QED. Learn more about QED's clinical trials, which are currently enrolling. Learn more about QED. Therapeutics Pipeline. www.qedtx.com/discover/infigratinib |
